National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Liposomal daunorubicin and cytarabine (Vyxeos Liposomal®) for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes.


NCPE Assessment Process Complete
Rapid review commissioned 28/09/2018
Rapid review completed 08/11/2018
Rapid Review outcome A Full Pharmacoeconomic Assessment is recommended
Full pharmacoeconomic assessment commissioned by HSE 14/11/2018
Pre-submission consultation with Applicant 15/01/2019
Submission received from Applicant 31/05/2019
HTA assessment commenced 04/09/2019
Preliminary review sent to Applicant 02/10/2019
NCPE assessment re-commenced 06/11/2019
Factual accuracy sent to Applicant 28/02/2020
NCPE assessment re-commenced 09/03/2020
NCPE assessment completed 16/04/2020
NCPE assessment outcome The NCPE recommends that Liposomal daunorubicin and cytarabine (Vyxeos Liposomal®) not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.